Raythera Inc. has described C-C chemokine receptor type 4 (CCR4) antagonists reported to be useful for the treatment of cancer, inflammatory bowel disease, psoriasis, systemic lupus erythematosus, atherosclerosis, asthma, chronic obstructive pulmonary disease and multiple sclerosis, among others.

Scientists at Hyperway Pharmaceutical Co. Ltd. and Shenzhen Hyperway Pharmaceuticals Co. Ltd. have divulged GTPase KRAS (mutant) inhibitors reported to be useful for the treatment of cancer, LEOPARD and Noonan syndromes.

Fauna Bio Inc. has identified 5-HT3 receptor antagonists reported to be useful for the treatment of cardiovascular and respiratory disorders.

Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd. has synthesized Myt1 kinase (PKMYT1) inhibitors reported to be useful for the treatment of cancer.

Beijing Double-Crane Runchuang Technology Co. Ltd. has disclosed protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.

Kallyope has divulged compounds acting as tachykinin NK3 receptor antagonists reported to be useful for the treatment of migraine.

Alphina Therapeutics Inc. has described nicotinamide phosphoribosyltransferase (NAmPRTase; Nampt) inhibitors reported to be useful for the treatment of cancer, and autoimmune, inflammatory and metabolic disorders.

Scientists at Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have identified relaxin receptor 1 (RXFP1; LGR7) agonists reported to be useful for the treatment of heart failure, chronic kidney disease, acute kidney injury, fibrosis and inflammatory disorders.

Iambic Therapeutics Inc. has synthesized kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of cancer.

Blueprint Medicines Corp. has disclosed EGFR mutant inhibitors reported to be useful for the treatment of non-small-cell lung cancer (NSCLC).